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Abstract 
Introduction: In etiology of Alzheimer’s disease (AD), involvement of amyloid β (Aβ) plaque 
accumulation and oxidative stress in the brain have important roles. Several nanoparticles such as 
titanium dioxide, silica dioxide, silver and zinc oxide have been experimentally using for treatment 
of neurological disease. In the last decade, there has been a great interest on combination of 
antioxidant bioactive compounds such as selenium (Se) and flavonoids with the oxidant 
nanoparticles in AD. We evaluated the most current data available on the physiological effects of 
oxidant and antioxidant nanoparticles.   
Areas covered: Oxidative nanoparticles decreased the activities of reactive oxygen species (ROS) 
scavenging enzymes such as glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and 
catalase in the brain of rats and mice. However, Se-rich nanoparticles in small size (5-15 nm) 
depleted Aβ formation through decreasing ROS production. Reports on low levels of Se in blood 
and tissue samples and the low activities of GSH-Px, catalase and SOD enzymes in AD patients and 
animal models support the proposed crucial role of oxidative stress in the pathogenesis of AD. 
Expert Commentary: In conclusion, present literature suggests that Se-rich nanoparticles appeared 
to be a potential therapeutic compound for the treatment of AD. 
KEYWORDS; Alzheimer’s disease, brain, nanoparticles, selenium, oxidative stress.  
 
 
 
 
 
 
  
 
1. Introduction 
Metal-rich nanoparticles are between 1 and 200 nm in size and they possess special 
physicochemical characteristics [1]. In the last decade, the effects of nanoparticles on human 
diseases including neurological diseases such as Alzheimer’s disease (AD) and dementia has been 
extensively studied. The experimental animals were treated with metal-rich nanoparticles via 
inhalation [2], oral supplementation [3], intratracheal [4], intravenous and intraperitoneal injection 
[5]. The metal-rich nanoparticles such as titanium dioxide (TiO2), silica dioxide (SiO2), silver and 
zinc oxide (ZnO) are absorbed into the body via the digestive tract, skin and also through inhalation 
(Table 1). These absorbed particles are stored in different organs but the brain is the most 
vulnerable to their oxidative toxic effects [6].  
Brain and neurons are particularly vulnerable to oxidative stress-induced damage due to the 
following three reasons: (1) their high amount of oxygen consumption (The brain utilizes 
approximately 25% of the body's total oxygen consumption), (2) the presence of high amount of 
polyunsaturated fatty acids, and (3) low levels of enzymatic antioxidant activity [7,8]. Metal-rich 
nanoparticles enhance the production of reactive oxygen species (ROS). The main targets of 
reactive oxygen species (ROS) are the lipids (lipid peroxidation), proteins (protein-carbonyl 
formation) and nucleic acids (RNA and DNA oxidation, double- and single strand break of DNA). 
The ROS are scavenged by enzymatic and non-enzymatic antioxidants. Enzymatic antioxidant 
glutathione peroxidase (GSH-Px) contains selenium as co-factor. Hydrogen peroxide (H2O2) is 
converted to water by the catalytic effects of GSH-Px. Selenium can also have direct antioxidant 
effect on brain and neurons [8]. Selenium forms several allotropes (red, black and gray) that 
interconvert with temperature changes. It has two opposite physiological features. Concentration-
dependently selenium can exert either its therapeutic or toxic effects.  High doses of selenium 
promotes the proliferation of  cancer cells  and has neurotoxic effects, although low and 
intermediate doses inhibit cancer cell proliferation and has a therapeutic effects on neurological 
diseases including  AD.  Antioxidant and anti-inflammatory effects of selenium were observed in 
vitro using cell lines and in vivo in animal models [9]. In addition, there is direct relationship 
between the evoked effect and the type of selenium compounds administered [10]. However, the 
results on the effects of selenium and selenium nanoparticles for the treatment of neuronal diseases 
are conflicting. These conflicting results can be in part attributed to the different concentrations 
used in experiments, and to the different cell lines used in in vitro assays. Oxidative stress is one of 
the main factors involved in the pathogenesis of many neurological diseases. Therefore, therapies 
using natural antioxidants compounds have been developed to cure several neurodegenerative 
diseases [11,12]. However, the success rate of treatments with natural antioxidants is low. 
Therefore, there is an urgent need for development of new nanoparticles with diagnostic and/or 
therapeutic properties to improve the detection and treatment of neurological diseases. 
Accumulating evidences indicate that there is a direct relationship between deficiency of selenium 
in serum and hair samples and memory deficit in patients with AD [13-16].  It has been reported 
that selenium treatment may decrease the risk of memory deficits in animal models and in AD 
patients [17,18]. Recently, high interest emerged to study the role of selenium and selenoproteins in 
neurodegenerative diseases including AD (Table 2). Selenoproteins are proteins containing 
selenium in the form of amino acid, selenocysteine.  Selenoproteins are mainly expressed in the 
human brain and most likely involved in antioxidant processes, which are the key factor in 
preventing the onset and progression of AD [19]. In addition, there are some newly synthesized 
selenoproteins and selenium nanoparticles possessing remarkable physiological properties [20,21]. 
Due to the high potency and low systemic toxicity of these particles, they might serve as 
alternatives for conventional therapeutic drugs for the treatment of neurological diseases including 
AD. 
In this review, we aimed to summarize the oxidant and antioxidant effects of nanoparticles 
in the brain. We also reviewed the potential therapeutic application of selenium nanoparticles for 
the treatment of AD. This review is expected to be a useful resource for the scientists working in the 
field of neurodegenerative diseases, oxidative brain injury or selenium-based drug development.  
2. Role of selenium on oxidative stress in Alzheimer disease (AD) 
There are two major types of free radical species: ROS and reactive nitrogen species (RNS). 
ROS are chemically reactive species containing oxygen. Examples include peroxides, superoxide, 
hydroxyl radical, and singlet oxygen. They are produced during the physiological processes. For 
example, engulfed bacteria and viruses in the neutrophils are killed by the ROS. Both ROS and 
RNS are produced in brain as a result of exposure to environmental factors such as electromagnetic 
radiation and industrial element pollution [22,23]. Toxic nanoparticles, for example aluminum or 
manganese oxide nanoparticles, from air pollution can induce excessive ROS production and 
oxidative stress in the brain. They can accelerate the progression of neurodegenerative diseases such 
as AD, amyloid lateral sclerosis and Parkinson’s disease [23]. If the amount of ROS will not be 
controlled by antioxidants, they will cause significant reversible or irreversible damage to a wide 
range of biological molecules, including nucleic acids, lipids and proteins or any nearby molecule 
causing a cascade of chain reactions [24]. There is considerable interest in the ROS-induced 
reactions, and their relationship in the physiology and pathology of AD [10].  
Oxidative stress was considered to be one of the main factors in the etiology of AD. AD is 
the world’s most common form of dementia. Incidence of AD is still increasing in the world and the 
development of new strategies is needed for the treatment of AD. Despite the high number of 
studies, the molecular mechanisms responsible for the initiation of AD have not been elucidated 
yet. There are many theories to explain the cause of Alzheimer's disease. i.) accumulation of 
amyloid precursor protein forming amyloid-β (Aβ) plaques, ii) hyperphosphorylation of tau protein, 
iii) oxidative stress, iv) alterations in cholinergic neurotransmission v) environmental pollution vi) 
genetic factors including mutations of amyloid precursor protein (APP) and presenilin (PSEN) 
genes, vi) immune system dysfunction, etc. [17,25,26]. Pathologically, the extracellular depositions 
of Aβ proteins and the presence of intraneuronal neurofibrillary tangles are important markers for 
posthumous diagnosis of AD. Aβ is the main protein component of senile plaques in the AD brain 
and it is composed of spontaneously aggregating peptides of 39-43 amino acids [17,27]. It is also 
known that microglia is the main source of neuroinflammatory factors and neuroinflammatory 
factors affect the nature of AD [17].  Inflammatory processes are associated with ROS production. 
Both ROS and RNS are considered to play important roles in induction of AD [11,28]. Moreover, 
Aβ fragment 25-35 (Aβ25–35) induces activation of inducible nitric oxide (NO) synthase [29] and 
protein oxidation in hippocampal fibroblasts derived from AD patients [30] and they are appeared 
to be responsible for ROS and RNS-induced hippocampal damage. In addition, the ROS and RNS 
initiate other injury processes such as neuroinflammation and protein misfolding in the AD brain 
[31,32]. There are some reports showing that sulfur atoms are also involved in the oxidation 
process. For example, the oxidative stress-inducing properties of Aβ-peptide (1-42) are totally 
abolished by substitution of the sulfur atom of metionin at position 35 with a methylene group [33]. 
Selenium is an essential trace element in our body. One of the most important selenium-
dependent detoxifying processes is associated with the activity of GSH-Px enzyme. GSH-Px protein 
contains a selenocysteine (Se-Cys) moiety in its active site. GSH-Px, catalase and SOD enzymes 
have synergistic functions in the removal of H2O2 and organic peroxides [8]. GSH-Px catalyzes a 
reaction, in which 2 reduced monomeric glutathione (GSH) react with H2O2, and form oxidized 
glutathione (GS-SG) and H2O. GSH contains thiol groups in its structure. GS-SG is reduced back to 
its thiol form (GSH) by the glutathione reductase enzyme [19]. 
Thioredoxins are small peptides in the cytosol and mitochondria and also play an important 
role in maintaining a reduced environment in the cells through thiol-disulfide exchange reactions 
and protects cells and tissues from oxidative stress [34]. Reduction of thioredoxin is catalyzed by 
thioredoxin reductase-1 (Trx1) and most radicals such as hydrogen peroxide (H2O2) and nitric oxide 
(NO) are scavenged by Trx1 (Figure 1).  
Besides of the neuronal injury evoked by hyperphosphorilated tau and Aβ plaques, 
accumulating evidences indicate the involvement of oxidative stress in apoptotic neuronal loss 
observed in the AD brain [35]. Since antioxidants are able to inhibit of Aβ aggregation pathways, 
new therapies have been developed for the treatment of AD. As it was mentioned above, 
thioredoxin (Trx) and glutathione (GSH) are the two major systems which play an important role in 
the maintenance of cellular redox homeostasis (Figure 1).  It was reported that the inhibition of 
GSH synthesis resulted in an increase in Aβ-induced cell death and intracellular Aβ accumulation 
[36]. Decreased levels of selenium, GSH and GSH-Px were observed in model animals and in AD 
patients [37]. Correlation between the loss of cognitive function and plasma selenium levels was 
also observed in patients with AD. Therefore, the relevance of selenium and GSH redox system in 
patients with AD indicates their important roles in redox regulation [38]. Reduced selenium 
contents in plasma and hair were reported in the patients with AD and it was found a negative 
correlation between the selenium content in plasma and incidence of AD [39]. Moreover, selenium 
treatments decreased the levels of oxidative stress and Aβ formation in the brain of experimental 
animal models for AD [40,41]. Positive correlations between plasma and hair selenium deficiency 
and cognitive decline were reported in patients with AD [15,16]. Recently, selenium, total tau, 
Aβ42, GSH, lipid peroxidation and antioxidant enzyme values were analyzed in the blood samples 
from AD patients in South India. No correlations were reported between the levels of selenium, 
total tau and Aβ42 [42]. On the contrary, decreased GSH-Px enzyme activity and reduced levels of 
selenium were reported in erythrocytes [13] of patients with dementia and AD.   
 
2.1. Size dependent effects of metal-rich nanoparticles in brain and AD 
It is well known that the brain is the most vulnerable organ in body for oxidative stress-
induced neurodegenerative injuries such as cerebral ischemia [42,43] and traumatic brain injury 
[44]. In most neurodegenerative diseases, these injuries are irreversible. The nanoparticles are 
mostly oxidant and they could induce neuronal injury and impair brain cognitive functions in AD 
[39,45-48]. Recent in vivo studies in the experimental animals treated  intraperitoneal or oral with 
nanoparticles have shown that  metal-rich oxidative nanoparticles such as TiO2, ZnO, iron oxide, 
SiO2, silver and gold can pass the blood-brain barrier (BBA) and accumulate in the brain [23,49,50] 
(Table 1). For example, high transport rate of Ag nanoparticles from blood to brain via BBA was 
reported in brain of rats after injection a dose 5 mg/kg silver nanoparticles (20 and 200 nm) for 28 
days. In addition, there is low rate of excretion from the brain and this leads to a gradual 
accumulation of nanoparticles in the brain. Contrary to intraperitoneal and oral applications, no 
accumulation of TiO2 nanoparticles in the brain area via nasal application was reported in mice 
[51]. 
Apart from the oxidant nanoparticles, there are nanoparticles with antioxidant properties, for 
instance selenium. Metabolism of selenium nanoparticles in cells were reported in a recent paper 
[52] and it was also summarized in Figure 1. Mitochondria are physiologically the main source of 
ROS such as superoxide and hydroxyl radicals in mammalian cells during normal energy 
metabolisms [53].  
Selenium consumed in foods and supplements exists in a number of forms including 
selenomethionine, selenocysteine, selenate and selenite. Reduced form of sodium selenite is 
selenide and it is produced in cytosol by catalytic effects of the GSH and superoxide radicals [54]. 
Then, the selenide is transformed to methylselenol and it is further transformed to methylated 
metabolites [55]. In addition, the selenide in cytosol serves as a source for selenoproteins, selenium-
sugar, and elemental selenium. In a recent study, high amount of elemental selenium was indicated 
in human lung cancer cell line treated with sodium selenite [56].  
Oxidative properties of nanoparticles are affected by physicochemical and biochemical 
factors such as surface properties, charge, and the adsorption rate of the nanoparticles [57]. In 
addition to these factors, the size of nanoparticles is an important factor which influences their 
biological activity. The large size of nanoparticle decreases its transport into brain and it is also 
constantly clearing foreign materials from the brain [45-48]. Redox regulatory and ROS scavenging 
activities of the selenium nanoparticles with different sizes has been reported [58]. ROS scavenging 
effects of red selenium nanoparticles with small (5-15 nm), medium (20-60 nm) and large (80-200 
nm) sizes were investigated in an in vitro model and the highest ROS scavenging effect was 
observed in the case of small-size red selenium nanoparticles [58]. Red elemental selenium 
nanoparticles with 20-60 nm sizes are produced from sodium selenite by the activated GSH redox 
system and they induced the proliferation rate of human hepatic cancer cells in vitro. They induced 
an increased activity of GSH-Px and Trx1 enzymes compared to sodium selenite [20]. On the 
contrary, Zhang and colleagues [59] reported that GSH-Px and Trx1 activities were affected neither 
in human hepatoma HepG2 cells nor in the mice liver by administration of selenium-rich 
nanoparticles in a size range of 5 to 200 nm. Similarly, chitosan nanoparticles with small size (40 
and 70 nm) were more active and toxic tested on cancer cells [60]. In addition, size dependent 
protective effect of selenium nanoparticles against ROS production and DNA damage has been 
found [61]. More recently, the protective role of dextrin coated selenium nanoparticles (64 nm)-
treated rats were investigated in the rat model of chronic inflammatory arthritis [56]. Increased 
SOD, GSH-Px and catalase activities were reported in liver, kidney and spleen of rats treated with 
dextrin-coated selenium nanoparticles [63,64]. According to the present literature, it seems that the 
small size range of selenium will ensure longer circulation time and increased accumulation in the 
brain of patients with AD 
 
3. Role of nanoparticles in the brain  
The presence of metals in the brain can be physiologically a necessity as well as a poison. 
Accumulation of the metals in brain tissues occur not only in the form of free ions, but also in the 
form of metalloproteins [23]. Abnormal homeostasis of metal ions in brain may induce neuronal 
damage if their levels move out of the normal physiological range especially due to the lack of 
specific metal binding proteins [39].  Biometals play significant roles in the biological systems 
through regulating and participating in numerous cellular processes such as induction of action 
potential and co-factor of enzymes [54]. In particular, homeostasis of these elements has been 
demonstrated to be critical in brain, because they are involved in enzymatic activities, 
mitochondrial function, myelination, and neurotransmitter release [19].  
The well-known metal-rich nanoparticles such as TiO2, ZnO, iron oxide, SiO2, silver (Ag) 
and gold (Au) have mostly oxidative effect in the brain [23,39]. On the contrary, selenium rich 
nanoparticles with antioxidant properties such as red selenium and sodium selenite are used in 
treatment of brain diseases and they size-dependently improve cognitive functions. In the following 
sections we will review recent reports on metal-rich nanoparticles such as TiO2, ZnO, SiO2 and 
silver. 
 
3.1. Effects of TiO2 and silica nanoparticles on antioxidant enzyme activity in the brain: TiO2 
nanoparticles are of high stability and have anticorrosion properties. They have been used for the 
treatment of neurological disease in experimental animals. However, potential toxic effects of TiO2 
have not been clarified yet.  
Decreased activities of GSH-Px, catalase and SOD in the mouse brain samples were 
reported after nasal application of TiO2 nanoparticles [51]. Results of another study indicated that 
activities of SOD and GSH-Px are decreased in the brain cortex and hippocampus region after oral 
administration of TiO2 with/without lead acetate [3] and the study concluded that TiO2-induced 
oxidative toxicity is supported by lead acetate. Ze and colleagues [64] investigated brain injury by 
nasal administration of different doses of TiO2 (2.5, 5, and 10 mg/kg) for 90 consecutive days.  
They performed oxidant and antioxidant analyses and analyzed the gene expression profile of the 
brain samples. They observed that the levels of malondialdehyde (MDA) and protein carbonyls as 
markers of oxidative stress in the mouse brain were higher in the three treated group than in the 
control. Another study reported that inhalation of silica nanoparticles decreased GSH-Px, catalase 
and SOD activities in the rat corpus striatum [55]. Microglia is the main phagocytic neuronal cells 
in the brain and they play an important role in the process of inflammation. Recently, positive role 
of silica nanoparticles on excessive ROS, RNS and cytokine production, and increased expression 
level of proinflammatory genes were reported in primary rat microglia [66].  
3.2. Effects of ZnO on the activity of antioxidant enzymes in the brain: ZnO nanoparticles are 
commonly used in many commercial products such as construction material, toothpaste, beauty 
material, and wall paints. The ZnO nanoparticles attract specific attention in medical area due to 
small size and high specific surface area. The toxic effect of ZnO nanoparticles has been well 
known in experimental animals and cell lines. ZnO nanoparticles are toxic for different tissues, 
including the brain [67].  
There are limited reports on how ZnO influence GSH-Px enzyme activity in the brain or 
neuronal cell lines. In a study, the effects of ZnO on oxidative stress and inflammation were 
investigated on brain samples from adult and old male mice. Intraperitoneal injection of ZnO 
nanoparticles decreased the activities of SOD and GSH-Px enzymes but MDA levels were 
increased [68].  
 
3.3. Effects of CuO and silver nanoparticles on the activity of antioxidant enzymes in the 
brain: Expression levels of antioxidant enzymes in neurons are differently affected by CuO, 
manganese and silver. For example, Wang et al. [69] reported that expression of Trx1 is increased 
in PC12 neuronal cell line by incubation with copper but not with manganese and silver. However, 
GSH-Px expression in the cell line was decreased by the copper and silver nanoparticles but its 
expression level was not affected by manganese.  
Dziendzikowska et al. [70] reported that silver nanoparticles caused neuronal oxidative 
damage through excessive ROS production and directly interfered with calcium responses in 
primary neural cells. Moreover, oxidative stress-induced GSH gene expression levels changed in  
caudate nucleus of the striatum, frontal cortex and hippocampus after administration of 25 nm Ag 
nanoparticles to mice [71]. Similarly, Hritcu and colleagues [5] reported that SOD and GSH-Px 
activities in temporal cortex of rat brain were decreased by intraperitoneal treatments of two doses 
(23 and 29 nm) of Ag nanoparticles for 7 days, although lipid peroxidation level as MDA were 
increased in the brain area. 
3.4. Effects of cerium dioxide (CeO2) and on the activity of antioxidant enzymes in AD: CeO2 
nanoparticles as coating agent protecting from corrosion in mechanical polishing were extensively 
used in addition to its utilization as diesel fuel additive [72]. It was reported that activities of several 
antioxidant enzymes such as GSH-Px, catalase and SOD are generally increased by CeO2 
nanoparticle treatments although excessive production of ROS decreased [72]. Recent reports 
indicated potential catalytic antioxidant role of CeO2 nanoparticles in AD [73,74]. Decreased level 
of Aβ plaque formation and oxidative stress in cortical neurons was reported by CeO2 nanoparticles 
through regulation of mitochondrial function [74]. Result of a recent study indicated that Cu2+-
induced Aβ aggregation and ROS production were decreased by CeNP@MnMoS4 Core-Shell 
nanoparticles [75]. In addition, Aβ-mediated toxicity was also decreased by CeONP@POMD 
nanoparticles [76]. The antioxidant enzyme-mimetic activity of CeO2 nanoparticles were attributed 
to the auto-regenerative cycle of Ce3+/Ce4+ and oxygen vacancies on the surface of CeO2 [72]. 
Therefore, it seems that CeO2 nanoparticles have protective effects against oxidative stress in AD 
supporting antioxidant enzyme activities.  
 
4. Protective role of nanoparticles for treatment of AD  
As it was mentioned above, AD is the world’s most common form of dementia characterized 
by the Aβ plaque accumulation, tau protein hyperphosphorylation, oxidative stress, and cell 
apoptosis in the brain [17,77]. Accumulating evidences indicated that Aβ polymerization may be 
crucial to AD pathologies [27]. Hence, there is a considerable effort to develop new drugs that 
inhibit Aβ fibrillation. Recently, nanoparticles such as sialic acid-modified selenium nanoparticles 
[41] and silver [69] nanoparticles have been investigated and their effects on AD are summarized in 
the following sections. 
 
4.1. Role of selenium nanoparticles in AD: As mentioned above, trace element selenium as an 
essential nutrient has important health effect in human biology [64]. Accumulating evidences 
indicate the important role of selenium in redox regulation because there are considerable data on 
positive correlation between increased cognitive decline and decreased selenium level [70]. The 
redox cycles of selenium (II), sodium selenate (VI) and sodium selenite (IV) forms are thought to 
be the most important mechanism linked to biological systems in brain by the inhibition of ROS 
[19]. Over the last decades, involvement of oxidative stress in neurological diseases such as 
dementia [18] and AD [10,41] have been extensively investigated. Different forms and sizes of 
selenium can influence its performance. The elemental selenium nanoparticles have size between 20 
and 500 nm and they are also referred to as red or elemental selenium. However, the size of red 
elemental selenium formed was dependent on the amount of protein in the redox system. For 
example, it was reported in two recent studies that selenium nanoparticles between 20 and 60 nm in 
size has similar bioavailability to sodium selenite [20,21]. Over the last decade, other selenium 
containing antioxidant nanoparticles attracted high interest in human neurobiology due to their 
inhibitory effects on oxidative stress and their excellent low toxicity [20]. The effects of sialic acid-
modified selenium nanoparticles in PC12 neuronal cell line were investigated by analyses of 
cytotoxicity, mitochondrial membrane depolarization-induced oxidative stress and apoptosis levels. 
The potential therapeutic application of sialic acid-modified selenium nanoparticles coated with B6 
peptide has been reported. It inhibited Aβ aggregation and crossed the BBA [41]. Main phenol 
component of green tea is epigallocatechin-3-gallate and it has antioxidant role against oxidative 
stress in cells and protective role of epigallocatechin-3-gallate-stabilized selenium nanoparticles on 
Aβ aggregation and amyloid fibril disaggregation was reported in in vitro model [37]. Some tree 
species (i.e. Oroxylum indicum) and flowers produce a flavonoid chrysin (5,7- dihydroxyflavone). 
The protective role of chrysin loaded solid lipid nanoparticles against Aβ25–35 induced oxidative 
stress was recently reported in rat hippocampal region [32]. Wang and colleagues [26] investigated 
involvement of selenium-containing clioquinol derivatives on Cu(II)-induced Aβ oxidation and they 
were observed beneficial effects of the selenium containing clioquinol derivatives on hydrogen 
peroxide scavenging activity, intracellular ROS production and Cu2+-induced Aβ aggregation in 
SH-SY5Y neuroblastoma cell line. Gupta et al. [78] investigated potential therapeutic effects of 
water soluble biphenyl ethers-coree shell CdSe/ZnS quantum dots on Aβ fiber in an in vitro model 
and they observed direct inhibitory effects of the dots on Aβ fiber formation. 
 
4.2. Role of silver nanoparticles in AD: There is limited report on how Ag-rich nanoparticles 
influence redox status. Huang et al. [79] investigated the toxic effects of Ag-rich nanoparticles on 
induction and progression of AD in three neuronal cell lines (murine brain ALT astrocytes, murine 
microglial BV-2 cells and mouse neuroblastoma Neuro-2a). After the exposure, these neural cells 
had increased inflammatory cytokine secretion and signs of oxidative stress. Additionally, this 
study found Aβ plaque formation deposited in neural cells after Ag-rich nanoparticles treatment.  
 
5. Expert commentary  
Selenium compounds are potent neuroprotective agents, with modest effect on normal tissues and 
clinically well tolerated. The exact mechanism of their neuroprotective action has not been solved 
completely, though numerous mechanisms have been proposed depending on compound and 
system examined. Low selenium levels in blood, hair and tissue samples from AD patients were 
reported. Diagnosis of AD is difficult because it can be confused with other neurological diseases. 
Therefore, there is need for new diagnostic markers and low selenium level and GSH-Px activity 
might serve as diagnostic markers of AD.  
Apart from the diagnosis, there are six main future directions and expert’s recommendation 
for this issue. There are only few reports on the application of selenium nanoparticles for the 
treatment of AD. Additional studies should be performed using nanoparticles as potential 
therapeutic neuroprotective agents in cell lines and experimental animals.  
In addition, there are limited reports on interactions between selenium-rich nanoparticles 
and neuronal cells and the available reports are conflicting (Tables 1). Hence, effects of the 
selenium nanoparticles on the activity of GSH-Px should be investigated by further experiments.  
Third, there are not enough reports on bio-distribution of oxidant and antioxidant 
nanoparticles in different brain areas. It is well known that each brain area is responsible for 
different physiological functions and hippocampus region is initially affected in AD. Therefore, 
clarifying the third subject is important to understand the etiopathogenesis of oxidative stress-
induced neurological diseases. 
Forth, changing the physicochemical structures of metal-rich nanoparticles may decrease 
their oxidative properties, resulting in their reduced oxidative toxicity in brain and neurological 
disease. The subject should be investigated in future studies by using different size of oxidant 
nanoparticles including ZnO and silver.  
Fifth, the potential therapeutic effects of selenium nanoparticles on AD should be tested 
properly in animal models and in clinical trials.  
Sixth, interactions between selenium nanoparticles and calcium ion (Ca2+) homeostasis 
should be investigated in neurons. The Ca2+ plays a crucial physiological role in physiological and 
pathophysiological functions such as apoptosis and mitochondrial functions [53,81]. Alteration in 
the function of Ca2+ entry channels on the plasma membrane including voltage gated calcium 
channels (VGCC) and transient receptor potential (TRP) cation channels play also an important role 
in oxidative stress-induced apoptosis and mitochondrial overload of Ca2+ [82]. Some transient TRP 
channels such as TRP melastatin 2 (TRPM2) and TRP vanilloid 1 (TRPV1) are modulated by 
different stimuli, including altered extracellular ionic milieu and metal cations [83]. A growing 
amount of evidence has shown that increased levels of  Ca2+ entry through TRPM2 and TRPV1 
channels induces excessive ROS production via increased depolarization membrane rate of 
mitochondria [12].  Since neurons express higher levels of TRPV1 channels compared to epithelial 
or cancer cells, neurons are more vulnerable [84,85]. Recently, we observed a modulator role of 
selenium on excessive ROS production and increased mitochondrial membrane depolarization via 
inhibition of TRPM2, TRPV1 channel activity in hippocampus of dementia and diabetes-induced 
rats [18,80]. Contrary to our reports, increased intracellular Ca2+ concentration was reported in 
primary cultures of rat hippocampal neurons by CdSe quantum dots (nanocrystals) through 
activation of VGCC [81]. In the conversion of selenide into elemental selenium, ROS plays an 
important role [52]. Overload Ca2+ entry via TRPM2, TRPV1 and VGCC may induce mitochondrial 
membrane depolarization and excessive ROS production increasing the levels of elemental 
selenium. This, in turn, may induce an increase in the production of GSH-Px enzyme leading to a 
decrease of ROS in neurons (negative feedback mechanism). This issue should be clarified by a 
study on neuronal cell lines or primary neuronal culture.    
 
6. Five year review 
ROS production occurs during the normal physiological function of our body. Physiological levels 
of ROS are not toxic if they are controlled by antioxidants enzymes and proteins such as GSH-Px. 
Etiology of AD has not been clarified although oxidative stress can be an important factor in this 
process. In addition, diagnosis of AD with continuous monitoring of dementia is not easy. 
Therefore, plasma selenium level and GSH-Px activity might be a diagnostic indicator of old 
patients with AD. Nanoparticles are used for commercial purposes such as leather production, 
cosmetics, microelectronics, and drug carriers and accumulating evidences indicated their 
environmental toxic effects [86]. In addition of their application in the commercial area, the 
nanoparticles are used in last decade for the treatment of diseases such as cancer and neurological 
diseases. Most metal-rich drug nanoparticles such as ZnO and TiO2 have been extensively 
investigated in cancer research and they are used as a therapeutical agent for cancer treatment [87]. 
Some metal-rich nanoparticles are proposed to be used in the treatment of neurological diseases, 
including AD but they influence brain functions. The threatening effects of the nanoparticles are 
drived from their ability to stimulate of ROS production and generate inflammation. In addition, the 
excessive accumulation of cytosolic metal-rich nanoparticles in the brain is another problem 
originated from high transport rate of the nanoparticles via BB [88,89]. In order to inhibit the 
oxidant effects of nanoparticles, studies with antioxidant covered nanoparticles such as selenium 
and flavonoid-covered selenium nanoparticles have been already introduced for the treatments of 
AD [26,32]. Selenium-rich nanoparticles inhibited formation and oxidation of Aβ in experimental 
animals and cell lines with AD. Yet, there is no human study on Aβ-formation although they are 
several studies on other metal-rich nanoparticles such as ZnO and TiO2. Hence, there is a need to 
study the effects of selenium-rich nanoparticles on human samples. The metal-rich nanoparticles 
have beneficial effects via excessive ROS production in cancer cells but selenium might have a 
therapeutic effect formation on in vitro models of AD via inhibition of excessive ROS production 
and Aβ formation.  Hence, decreased activity of antioxidant enzymes such as GSH-Px, SOD and 
catalase are reported by the metal-rich nanoparticles, whereas the enzyme activities are increased by 
selenium rich nanoparticles treatments. It seems that selenium and flavonoid enriched nanoparticles 
are important candidates for drug development to treat AD [26,32]. However, results of the limited 
studies are not enough to clarify the role of selenium-rich nanoparticles. Therefore, the putative 
correlations between improvement in AD symptoms and treatment with selenium nanoparticles 
require further studies. Normally, sizes of selenium rich nanoparticles are between 1-200 nm. ROS-
scavenging effectiveness of selenium-rich nanoparticles is affected by size and highest ROS-
scavenging activity was found in the case of small size nanoparticles (5 and 15 nm).  
 
 
7. Key issues 
• Investigation of selenium rich nanoparticles is important for drug development in AD. 
• There are serious unmet needs in the examination of the neuroprotective role of selenium-
rich nanoparticles in biological samples from experimental animal models and patients with 
AD. 
• The bio-distribution of selenium nanoparticles in brain areas should be investigated. 
• Further experiments are needed to clarify the main role of GSH-Px in AD patients. 
• Selenium nanoparticles differing in physicochemical properties and size should be tested 
focusing their inhibitory effect on oxidative stress.  
• Interactions of oxidative stress-related TRP channels such as TRPM2 and TRPV1 and 
selenium- rich nanoparticles can be also an important topic. 
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Table 1. Effects of nanoparticles on antioxidant enzymes in brain of experimental animals. 
 
Nanoparticle Administration 
route 
Material  Value/Effect Reference 
Ag Incubation PC12 cell line Trx1 and GSH-
Px/Trx1 expression 
level unchanged but 
GSH-Px expression 
decreased  
Wang et al. [69] 
Ag Intraperitoneal Caudate, frontal 
cortex and 
hippocampus of 
mice brain 
Glutathione gene 
expression 
Rahman et al. [71] 
Ag  Intraperitoneal Temporal cortex 
of rat 
SOD and GSH-Px/ 
Decreased 
Hritcu et al. [5] 
CuO Incubation PC12 cell line Expression level of 
Trx1 increased but 
GSH-Px expression 
decreased 
Wang et al. [69] 
 
Mn Incubation PC12 cell line Expression level of 
Trx1 and GSH-
Px/unchanged 
Wang et al. [69] 
 
TiO2 Nasal Mice brain GSH-Px, catalase 
and SOD/ Decreased 
Jeon et al. [51] 
TiO2 
with/without 
lead acetate  
Oral Brain cortex and 
hippocampus of 
mice 
SOD and GSH-Px/ 
Decreased 
Zhang et al. [3] 
ZnO Intraperitoneal Brain of adult and 
old male 
SOD and GSH-Px/ 
Decreased 
Vedagiri and 
Thangarajan [32] 
CAT; Catalase, GSH-Px; glutathione peroxidase, SOD; superoxide dismutase, Trx1; thioredoxin 
reductase 1,  
 
 
 
 
Table 2. In vivo and in vitro effects of nanoparticles on Alzheimer’s disease (AD) in cell line, 
humans and animals. 
Nanoparticle Material Value/Effect Reference 
 
Ag Neuronal cell 
lines 
Induction and progression 
of AD 
Huang et al. [73] 
Biphenyl ethers conjugated 
CdSe/ZnS core/ 
shell quantum dots  
In vitro Aβ 
model 
Aβ fibril disruption  Gupta et al. [78] 
Chrysin loaded solid lipid 
nanoparticles 
Rat  Protective and antioxidant 
effect 
Vedagiri and 
Thangarajan [32] 
Epigallocatechin-3-gallate-
stabilized selenium 
nanoparticles 
Aβ peptides Aβ aggregation and 
cytotoxicity/protective 
effect 
Zhang et al. [37] 
Sialic acid-modified Se PC12 neuronal 
cell line  
Crossing the blood-brain 
barrier and decreased level 
of Aβ aggregation and  
Yin et al. [41] 
Se-containing clioquinol 
derivatives 
Neuroblastoma 
cell line 
Cu(II)-induced Aβ 
oxidation and aggregation 
/protective effect 
Wang et al. [26] 
AD; Alzheimer’s Disease; GSH-Px, glutathione peroxidase; Se, selenium 
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by thioredoxin reductase-1 enzyme (Trx1) and many radicals such as H2O2 and nitric oxide are 
scavenged by Trx. Elemental selenium (Se0) from selenium rich nanoparticles is produced by 
catalytic effects of reduced GSH and mitochondrial ROS. Excessive Ca2+ entry through oxidative 
stress-activated TRP channels induce mitochondrial membrane depolarization and excessive ROS 
production. Interactions between TRP channel and selenium nanoparticles in AD should be 
investigated by future studies.    
